Long-term Outcome of Osteonecrosis of the Jaw after Fosamax Exposure

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Risk

The legacy of general health and science communication has long emphasized broad wellness principles, from anti-aging skin care to preventive medicine. In this tradition, public understanding of medication safety has been built around general awareness of side effects and the importance of informed patient choice. However, as medical knowledge deepens, the focus naturally narrows from population-level guidance to specific, high-stakes clinical scenarios. One such scenario involves the long-term use of bisphosphonates like Fosamax, originally prescribed to manage bone density concerns in aging populations. Over time, clinical observation has identified a rare but serious complication: osteonecrosis of the jaw (ONJ). This condition, characterized by exposed bone in the oral cavity that fails to heal, has shifted the conversation from general bone health maintenance to a more targeted risk assessment. The prognosis for patients who develop ONJ after Fosamax exposure varies widely, depending on factors such as the duration of drug use, the presence of dental procedures, and individual healing capacity. Understanding this long-term outcome requires moving beyond generic health advice into a nuanced evaluation of exposure history and patient-specific variables. This transition from broad health education to focused clinical concern underscores the evolving nature of medical communication, where once-routine treatments now demand careful scrutiny of their potential for lasting adverse effects.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed bone in the maxillofacial region that can occur spontaneously or be triggered by local factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ typically involves delayed healing after dental procedures, such as tooth extraction or dental implant placement, and may be accompanied by local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The condition is generally associated with invasive dental procedures, but can also arise spontaneously (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ involve the drug's antiresorptive action on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast activity, which can suppress normal bone turnover. In the jawbone, which has a high remodeling rate and is subject to frequent microtrauma from mastication, this suppression may impair the ability to repair microdamage and maintain bone health. A multiscale characterization of jawbone tissue has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research underscores the unique vulnerability of the jawbone to antiresorptive therapy.

Prognosis and Long-term Outcomes

The prognosis for patients who develop ONJ after Fosamax exposure varies. According to labeling information, the time to onset of symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the medication, although a subset may have recurrence of symptoms if rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that not all cases are directly attributable to the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Risk factors for developing ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that while the relative risk increases with prolonged exposure, the absolute risk for individual patients remains small.

Risk Context and Clinical Management

The adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's labeling. The prescribing information includes a specific section on osteonecrosis of the jaw under Warnings and Precautions, detailing the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that the optimal duration of use has not been determined and suggests considering drug discontinuation after 3 to 5 years for patients at low risk for fracture (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This guidance aligns with the observed timeline of increased risk with longer exposure. In summary, the long-term outcome of ONJ after Fosamax exposure is generally favorable with discontinuation of the drug, though recurrence is possible with rechallenge. The condition is rare, with absolute risks remaining low even after extended use. Prognosis-related considerations include the importance of dental evaluation before initiating therapy, avoidance of invasive dental procedures during treatment when possible, and monitoring for symptoms. The timeline between exposure and documented harm can range from days to months, with risk increasing over years of use. Adequate warnings are provided in the prescribing information, but clinicians and patients should remain vigilant, especially in the presence of known risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for osteonecrosis of the jaw after Fosamax exposure?

Most patients experience relief of symptoms after discontinuing Fosamax, though a subset may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Absolute risk remains low, about 0.05% after 5 years of use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing osteonecrosis of the jaw from Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Longer duration of bisphosphonate use increases risk (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.